As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.
9 Analysts have issued a Atara Biotherapeutics Inc forecast:
9 Analysts have issued a Atara Biotherapeutics Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 189 189 |
202%
202%
|
|
| Gross Profit | 153 153 |
207%
207%
|
|
| EBITDA | 28 28 |
117%
117%
|
|
| EBIT (Operating Income) EBIT | 23 23 |
114%
114%
|
|
| Net Profit | 5.80 5.80 |
103%
103%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Anhco Nguyen |
| Employees | 153 |
| Founded | 2012 |
| Website | www.atarabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


